vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Loar Holdings Inc. (LOAR). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $131.8M, roughly 1.5× Loar Holdings Inc.). Loar Holdings Inc. runs the higher net margin — 9.5% vs -14.6%, a 24.1% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 19.3%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 19.8%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
AXSM vs LOAR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $131.8M |
| Net Profit | $-28.6M | $12.5M |
| Gross Margin | — | 52.1% |
| Operating Margin | -13.8% | 18.0% |
| Net Margin | -14.6% | 9.5% |
| Revenue YoY | 65.0% | 19.3% |
| Net Profit YoY | 61.9% | 239.5% |
| EPS (diluted) | $-0.55 | $0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $131.8M | ||
| Q3 25 | $171.0M | $126.8M | ||
| Q2 25 | $150.0M | $123.1M | ||
| Q1 25 | $121.5M | $114.7M | ||
| Q4 24 | $118.8M | $110.4M | ||
| Q3 24 | $104.8M | $103.5M | ||
| Q2 24 | $87.2M | $97.0M | ||
| Q1 24 | $75.0M | $91.8M |
| Q4 25 | $-28.6M | $12.5M | ||
| Q3 25 | $-47.2M | $27.6M | ||
| Q2 25 | $-48.0M | $16.7M | ||
| Q1 25 | $-59.4M | $15.3M | ||
| Q4 24 | $-74.9M | $3.7M | ||
| Q3 24 | $-64.6M | $8.7M | ||
| Q2 24 | $-79.3M | $7.6M | ||
| Q1 24 | $-68.4M | $2.2M |
| Q4 25 | — | 52.1% | ||
| Q3 25 | — | 52.7% | ||
| Q2 25 | — | 53.8% | ||
| Q1 25 | — | 52.1% | ||
| Q4 24 | — | 48.9% | ||
| Q3 24 | — | 51.1% | ||
| Q2 24 | — | 49.0% | ||
| Q1 24 | — | 48.4% |
| Q4 25 | -13.8% | 18.0% | ||
| Q3 25 | -27.0% | 22.9% | ||
| Q2 25 | -24.5% | 22.2% | ||
| Q1 25 | -46.9% | 22.8% | ||
| Q4 24 | -61.1% | 19.2% | ||
| Q3 24 | -59.8% | 22.1% | ||
| Q2 24 | -89.5% | 22.9% | ||
| Q1 24 | -89.7% | 23.3% |
| Q4 25 | -14.6% | 9.5% | ||
| Q3 25 | -27.6% | 21.8% | ||
| Q2 25 | -32.0% | 13.6% | ||
| Q1 25 | -48.9% | 13.4% | ||
| Q4 24 | -63.1% | 3.3% | ||
| Q3 24 | -61.7% | 8.4% | ||
| Q2 24 | -91.0% | 7.9% | ||
| Q1 24 | -91.1% | 2.4% |
| Q4 25 | $-0.55 | $0.13 | ||
| Q3 25 | $-0.94 | $0.29 | ||
| Q2 25 | $-0.97 | $0.17 | ||
| Q1 25 | $-1.22 | $0.16 | ||
| Q4 24 | $-1.54 | $-11023.48 | ||
| Q3 24 | $-1.34 | $0.09 | ||
| Q2 24 | $-1.67 | $0.09 | ||
| Q1 24 | $-1.44 | $11023.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $84.8M |
| Total DebtLower is stronger | — | $715.7M |
| Stockholders' EquityBook value | $88.3M | $1.2B |
| Total Assets | $689.8M | $2.0B |
| Debt / EquityLower = less leverage | — | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $84.8M | ||
| Q3 25 | $325.3M | $99.0M | ||
| Q2 25 | $303.0M | $103.3M | ||
| Q1 25 | $300.9M | $80.5M | ||
| Q4 24 | $315.4M | $54.1M | ||
| Q3 24 | $327.3M | $55.2M | ||
| Q2 24 | $315.7M | $73.2M | ||
| Q1 24 | $331.4M | $28.2M |
| Q4 25 | — | $715.7M | ||
| Q3 25 | — | $279.4M | ||
| Q2 25 | — | $277.7M | ||
| Q1 25 | — | $277.5M | ||
| Q4 24 | — | $277.3M | ||
| Q3 24 | — | $602.1M | ||
| Q2 24 | — | $250.7M | ||
| Q1 24 | — | $534.2M |
| Q4 25 | $88.3M | $1.2B | ||
| Q3 25 | $73.7M | $1.2B | ||
| Q2 25 | $73.1M | $1.1B | ||
| Q1 25 | $53.2M | $1.1B | ||
| Q4 24 | $57.0M | $1.1B | ||
| Q3 24 | $92.9M | $769.8M | ||
| Q2 24 | $102.9M | $758.4M | ||
| Q1 24 | $144.0M | $420.6M |
| Q4 25 | $689.8M | $2.0B | ||
| Q3 25 | $669.3M | $1.5B | ||
| Q2 25 | $639.8M | $1.5B | ||
| Q1 25 | $596.7M | $1.5B | ||
| Q4 24 | $568.5M | $1.5B | ||
| Q3 24 | $561.5M | $1.5B | ||
| Q2 24 | $548.2M | $1.1B | ||
| Q1 24 | $545.7M | $1.1B |
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 0.24× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | — | 0.25× | ||
| Q4 24 | — | 0.25× | ||
| Q3 24 | — | 0.78× | ||
| Q2 24 | — | 0.33× | ||
| Q1 24 | — | 1.27× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $30.4M |
| Free Cash FlowOCF − Capex | $-18.7M | — |
| FCF MarginFCF / Revenue | -9.6% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 2.43× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $30.4M | ||
| Q3 25 | $1.0M | $29.7M | ||
| Q2 25 | $-32.4M | $23.8M | ||
| Q1 25 | $-43.4M | $28.4M | ||
| Q4 24 | $-26.2M | $20.7M | ||
| Q3 24 | $-18.6M | $16.3M | ||
| Q2 24 | $-30.1M | $7.1M | ||
| Q1 24 | $-53.5M | $10.8M |
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $988.0K | — | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.7M | — | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.7M | — | ||
| Q2 24 | $-30.2M | — | ||
| Q1 24 | $-53.6M | — |
| Q4 25 | -9.6% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -36.0% | — | ||
| Q4 24 | -22.1% | — | ||
| Q3 24 | -17.9% | — | ||
| Q2 24 | -34.6% | — | ||
| Q1 24 | -71.4% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | 2.43× | ||
| Q3 25 | — | 1.08× | ||
| Q2 25 | — | 1.42× | ||
| Q1 25 | — | 1.85× | ||
| Q4 24 | — | 5.62× | ||
| Q3 24 | — | 1.89× | ||
| Q2 24 | — | 0.93× | ||
| Q1 24 | — | 4.81× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
LOAR
| Other | $76.8M | 58% |
| Commercial Aerospace | $21.2M | 16% |
| Business Jet And General Aviation | $17.6M | 13% |
| Defense | $16.2M | 12% |
